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PERSPECTIVE OPEN
The potential application of probiotics and prebiotics for the
prevention and treatment of COVID-19
Amin N. Olaimat 1✉, Iman Aolymat2, Murad Al-Holy1, Mutamed Ayyash 3✉, Mahmoud Abu Ghoush 1, Anas A. Al-Nabulsi4,
Tareq Osaili4,5, Vasso Apostolopoulos6, Shao-Quan Liu7 and Nagendra P. Shah8
COVID-19 is a pandemic disease caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
This new viral infection was first identified in China in December 2019, and it has subsequently spread globally. The lack of a
vaccine or curative treatment for COVID-19 necessitates a focus on other strategies to prevent and treat the infection. Probiotics
consist of single or mixed cultures of live microorganisms that can beneficially affect the host by maintaining the intestinal or lung
microbiota that play a major role in human health. At present, good scientific evidence exists to support the ability of probiotics to
boost human immunity, thereby preventing colonization by pathogens and reducing the incidence and severity of infections.
Herein, we present clinical studies of the use of probiotic supplementation to prevent or treat respiratory tract infections. These
data lead to promising benefits of probiotics in reducing the risk of COVID-19. Further studies should be conducted to assess the
ability of probiotics to combat COVID-19.
npj Science of Food            (2020) 4:17 ; https://doi.org/10.1038/s41538-020-00078-9
INTRODUCTION
The evolution and emergence of viruses have significantly
increased in the last two decades because of their rapid mutation.
The emergence or re-emergence of viruses is attributable to
several factors including increased numbers of immunocompro-
mised patients, climate change, the absence of anti-viral agents,
the increased geographical movement of people and goods, and
genetic modification of viruses1,2. Respiratory infections represent
a major cause of death and disability worldwide in both
developing and developed countries3. It has been estimated that
acute respiratory infections including pneumonia, influenza,
enterovirus, adenovirus, and respiratory syncytial virus infections
are responsible for millions of deaths every year. In addition, they
have a substantial economic and social impact because of their
associated high hospitalization rate, high medical costs, and losses
of productivity associated with time missed from work or school. It
has been estimated that the annual cost of viral respiratory tract
illnesses is approximately US $40 billion in the United States1. The
majority of these infections are caused by more than 200 different
types of viruses that may contain RNA or DNA as genetic material.
Infections related to RNA viruses are more remarkable than those
caused by DNA viruses. In particular, coronaviruses represent a
highly important emerging RNA virus family2.
CORONAVIRUS DISEASE 2019 (COVID-19)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a
novel coronavirus that causes coronavirus disease (COVID-19) in
humans, a respiratory infection that was first reported in Wuhan,
China in December 2019. This SARS-related coronavirus is a
member of the zoonotic beta-coronavirus family4,5. SARS-CoV-2 is
an enveloped virus with a single-stranded positive sense RNA
genome6. Coronaviruses are named for their crown-like shapes
associated with their long surface spikes7. Coronaviruses are
hosted by humans and several other vertebrate reservoirs such as
camels, bats, masked palm civets, mice, dogs, and cats8,9. It has
been suggested that COVID-19 was initially hosted by bats and
then transmitted to humans via wild animals; however, the
subsequent spread of the virus occurred through human-to-
human transmission7.
Coronaviruses may cause respiratory, gastrointestinal (GI), and
neurologic disorders8. Most of the identified coronaviruses cause
mild human disease excluding SARS-CoV-1 and Middle East
respiratory syndrome coronavirus (MERS-CoV), which are highly
pathogenic viruses associated with severe infections and fatal-
ities9,10. SARS-CoV-1 appeared in 2002 in China, whereas MERS-
CoV was identified in 2012 in Saudi Arabia4,8. Although SARS-CoV-
2 is more transmissible than MERS-CoV and SARS-CoV-1, it has
lower fatality rates than either virus8. COVID-19 is highly
pathogenic, and the number of affected patients has drastically
increased globally. Therefore, COVID-19 was declared pandemic
by WHO, which confirmed at least 32.5 million cases and more
than 986.000 deaths through September 26, 202010.
The incubation period for COVID-19 is 1–14 days10. The clinical
manifestations of COVID-19 are variable, ranging from asympto-
matic to severe illness. Asymptomatic patients can serve as
sources of disease dissemination5,8. Common symptoms of
COVID-19 include fever, dry cough, shortness of breath, myalgia,
and fatigue. Headache, rhinorrhea, sneezing, sore throat, loss of
odor and pneumonia are other reported symptoms of COVID-198.
Other uncommon manifestations of the disease include gastro-
intestinal symptoms such as diarrhea, nausea, vomiting, and
abdominal pain7,8.
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The majority of cases are self-limiting and result in complete
recovery5. Conversely, SARS-CoV-2 can cause severe infections and
result in septic shock, acute respiratory distress syndrome, acute
cardiac injury, acute kidney injury, and multi-organ failure, which
necessitate intensive care unit admission. Extremely severe cases
of COVID-19 can lead to death5,7,8. Adults and children usually
develop mild self-limiting disease. Meanwhile, more severe
COVID-19 can occur in elderly people with underlying medical
conditions such as cardiovascular diseases and diabetes5. Preg-
nant women usually develop a disease status similar to that in
non-pregnant adult patients. Although COVID-19 was initially
considered uncommon in children11, increasing numbers of
pediatric cases have been reported worldwide, suggesting that
children have the same susceptibility to COVID-19 as adults but
exhibit mild or asymptomatic disease12.
A history of contact with infected patients within 2 weeks
should raise the suspicion of COVID-19 infection7. Real-time
reverse-transcription–polymerase-chain-reaction is the gold stan-
dard diagnostic tool for COVID-19. Moreover, chest computed
tomography is another modality supporting the clinical diagnosis
of COVID-197.
COVID-19 is mainly transmitted from person-to-person via
sneeze- or cough-induced respiratory droplets from the mouths or
noses of infected persons5,8. Disease transmission through the
eyes has also been suggested. Contact with surfaces contami-
nated by the virus is another mode of COVID-19 transmission4,9.
Recently, SARS-CoV-2 was detected in stools, suggesting the
possibility of fecal–oral transmission13. This was later confirmed in
some cases in the US and China which indicated that SARS-CoV-2
can multiply in both respiratory and digestive tracts14. Further-
more, the fecal samples of some infected patients were found
positive for the RNA of SARS-CoV-2 after their respiratory samples
became negative for the viral RNA15. It seems that COVID-19
infection negatively affect the anatomy and physiology of the GI
tract for a long period and thus, attacking the gut microbiota16,17.
Nowadays, a solid body of available evidence confirmed that the
gut microbial community of COVID-19 patients had been
changed. It was obvious that growth of opportunistic pathogens
and reduction of beneficial bacteria in gut microbiota positively
correlated with the severity of COVID-19 infections18,19.
GUT MICROBIOTA
Vaccines are promising treatments for preventing viral infectious
disease; however, their efficacy can be limited by mutations in
RNA viruses, as observed for the influenza virus as a representative
pathogenic virus20,21. This increases the risk of infection, making
these viruses serious threats to public health because of recurrent
widespread outbreaks.
The microbial communities (bacteria, fungi, archaea, viruses,
and protozoa) in the human GI tract, lungs, skin, and mouth exist
in a commensal relationship with host cells, thereby playing a
major role in human health22,23. The commensal bacteria (1 × 1013
CFU) that are present in the GI tract are equivalent to the number
of human cells24. This colonization starts shortly after birth and
their profiles and numbers stabilize by the age of 1 year with more
than 1000 bacterial species25,26. The GI microbiota has the ability
to interact with human cells, including specific immune cells.
These interactions produce different health benefits in the host
including regulating GI motility; activating and destroying toxins,
genotoxins, and mutagens; transforming bile acid and steroids;
producing vitamins; absorbing minerals; metabolizing xenobiotic
substances; influencing intestinal permeability and barrier func-
tions; and modulating mucosal and systemic immunity; as well as
beneficial effects on the skin and upper respiratory tract26,27.
Recently, the presence of beneficial microbes was reported in
the upper (nasal cavity, nasopharynx, oropharynx, and larynx
above the vocal cords) and lower respiratory tracts (larynx below
the vocal cords, trachea, bronchi, and bronchioles and alveoli of
the lungs) of both healthy people and those with pulmonary
diseases such as cystic fibrosis and chronic obstructive pulmonary
disease20,28. The microbiota populated the lungs mostly via the
upper respiratory tract or diffusion along the mucosal surface28,29.
These beneficial microorganisms compete with pathogens
concerning the colonization of human cells in different organs
to promote host health. This requires high numbers of beneficial
microorganisms, and any imbalance or disruption of this system
may cause dysbiosis, which can allow pathogens to cause diseases
such as respiratory tract infections20,22. Dysbiosis can also be
caused by long-term antibiotic use. Therefore, probiotics are also
usually recommended for patients who have recently used
antibiotics for treating any disease. Other causes of dysbiosis in
the human GI tract include exposure to toxins, stress, disease,
insufficient diet, and age26.
GUT-LUNG AXIS AND COVID-19
The gastrointestinal tract and lung are among the body
compartments that host microbiota; however, the lung has a
small number of microbiota when compared to that of the gut30.
There is accumulating evidence that bidirectional communications
exist between gut and lung, which is called the gut-lung axis. This
bidirectional crosstalk is involved in the support of immune
homeostasis31. It is believed that the gastrointestinal inflammation
results in lung inflammation through this connection32. The exact
mechanism underlying this inflammatory shift from the gut to the
lung is not yet completely revealed; however, dysbiosis of gut and
lung microbiota is one of the implicated factors in this event. It has
been shown previously that dysbiosis of gut microbiota is linked
with several respiratory pathological conditions32,33, and shifts in
the composition of the lung microbiota toward the gut microbiota
have been observed in several respiratory disorders30,34. One of
the suggested mechanisms behind the bidirectional interaction
between lung and gut microbiota systems is that increased
permeability of the GI tract allows the leakage and migration of
the gut microbiota to the lung, modulating its microbiota and thus
its immune responses30. Furthermore, gut microbial components
and metabolites like lipopolysaccharides (LPS) and short-chain
fatty acids (SCFA), respectively, are also involved in this gut-lung
bidirectional communication. Additionally, blood- or lymphatic-
mediated circulation of immune cells or inflammatory mediators
from the GI tract to the lung results can in lung inflammatory
responses30,35.
In addition to the most frequently described respiratory
symptoms such as fever, cough and severe respiratory syndrome
caused by COVID-19 infection, it has also been reported that
patients exhibited GI symptoms including diarrhea, vomiting,
nausea, loss of appetite, GI bleeding, and abdominal pain36. It was
found that COVID-19 patients with GI symptoms such as diarrhea
experienced more severe respiratory disorders than those without
GI symptoms37. Although the impact of the gut on lung health is
well established, the available knowledge about the opposite role
of the lung on the gut health is still scarce. Therefore, it is
unknown why would COVID-19 influence the GI tract integrity.
Dysbiosis is potentially one of the contributing mechanisms. Little
knowledge is available about the effect of lung microbiome on the
gut one. Acute lung injury mediated-lung dysbiosis was associated
with blood-mediated modulation of the gut microbiota38,39, and
the gut microbiota population is modulated in cases of pulmonary
allergy40. As a result, COVID-19 may induce lung microbiota
disruption that modulates the GI tract microbiota, resulting in GI
tract symptoms.
Furthermore, studies revealed that the GI symptoms generated
in patients infected with COVID1-9 might be attributed to the
damaged tissues and organs caused by the immune responses41.
Alternatively, angiotensin-converting enzyme 2 (ACE2) is the main
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host cell receptor of COVID-1942,43. ACE-I and ACE-II are crucial
enzymes that play a significant role in regulating blood pressure
via the biochemical renin-angiotensin-aldosterone system (RAAS)
pathway44. Besides the lung, ACE2 is also expressed by the
intestines, and direct colonization of the gut ACE2 receptors
through the ingestion of the virus is potentially responsible for the
gastrointestinal tract symptoms associated with COVID-19. Instead
of that, dysfunction of apoptosis pathways in the intestine due to
respiratory infections45 is another proposed explanation for
COVID-19-associated GI tract symptoms. Additionally, it is still
likely COVID-19-related GI tract symptoms might result due to the
fact that GI tract and respiratory tracts share the same embryonic
origin, and thus they are structurally alike and interact similarly in
physiological and pathological conditions46. All these suggested
mechanisms can work individually or collectively to induce GI tract
disturbances associated with COVID-19.
To date, no vaccine has been developed for COVID-19, nor is
any curative therapy available. Most available treatments aim to
alleviate symptoms, and mechanical ventilation is used in cases of
severe disease. Some anti-viral, anti-inflammatory and anti-
malarial drugs have been applied to treat COVID-19; however,
none of these medications have been approved as effective
curative treatments against COVID-198. Therefore, other safe
strategies such as probiotics and prebiotics could be applied to
prevent or treat COVID-19.
PROBIOTICS AND PREBIOTICS
Probiotics are live microorganisms that confer a beneficial
physiological effect on the host when administered at adequate
amounts. Some lactic acid bacteria that can be found in different
fermented foods such as yogurt, cheese, and pickles are generally
recognized as safe and classified as probiotics because of their
health benefits47. It was suggested that probiotics should be
consumed daily at doses of 108 to 1010 CFU to produce health
benefits in humans. The approved health benefits include
reducing symptoms of lactose intolerance by improving lactose
digestion, inhibiting the initiation of allergic diseases, maintaining
intestinal pH, preventing or treating ischemic heart syndromes,
reducing blood cholesterol levels, producing vitamins B, improv-
ing the bioavailability of dietary calcium, and boosting immune
activity. Meanwhile, other potential health benefits such as the
treatment of acute diarrheal diseases and prevention of cancer
and tooth decay require additional research for validation22.
Probiotics include bacteria such as Lactobacillus acidophilus, L.
amylovorus, L. brevis, L. bulgaricus, L. casei, L. cellobiosus, L.
crispatus, L. curvatus, L. delbrueckii spp. bulgaris, L. fermentum, L.
gallinarum, L. helveticus, L. johnsonii, L. lactis, L. paracasei, L.
plantarum, L. reuteri, L. rhamnosus; Streptococcus thermophilus,
Lactococcus lactis, Leuconostoc mesenteroides, Pediococcus pento-
saceus, P. acidilactici, Bifidobacterium adolescentis, B. animalis, B.
bifidum, B. breve, B. essensis, B. infantis, B. laterosporum, B.
thermophilum, B. longum, Propionibacterium acidipropionici, P.
freudenreichii, P. jensenii, P. thoenii, Enterococcus fecalis, E. faecium,
Bacillus alcolophilus, B. cereus, B. clausii, B. coagulans, B. subtilis,
Escherichia coli, Sporolactobacillus inulinus; as well as yeast such as
Saccharomyces boulardii and S. cerevisiae48–50. Probiotics have
been proposed as antimicrobial agents against a large number of
pathogenic and spoilage bacteria. However direct and indirect
anti-viral activity was recently reported for some probiotic
strains51.
Prebiotics were initially defined as “non-digestible food
ingredients that beneficially affects the host by selectively
stimulating the growth and/or activity of one or a limited number
of bacteria already residing in the colon”52. The prebiotics
definition has been modified several times and finally it was
proposed as ‘substrates that are selectively utilized by host
microorganisms conferring a health benefit’53. Similar to
probiotics, prebiotics can be delivered into microbially colonized
body sites by oral administration to reach the intestines, or by a
direct way to the vaginal tract and skin53. Prebiotics include
fructans, oligosaccharides, arabinooligosaccharides, isomaltooligo-
saccharides, xylooligosaccharides, resistant starch, lactosucrose,
lactobionic acid, galactomannan, psyllium, polyphenols and
polyunsaturated fatty acids53–55. The health benefits of prebiotics
to the GI tract including inhibition of pathogens and stimulation of
immune system are due to their ability to modulate the
composition and activity of human microbiota55. However, to
date, there is no information directly linking prebiotics to COVID-
19 infections in any way, although a indirect effect may be
hypothesized.
PROBIOTICS AND IMMUNE MODULATION
Probiotic bacteria have been shown to have a number of
beneficial immune and health effects. They not only enhance
the bioavailability of nutrients and moderate health, they are also
involved in regulating the bacterial ecosystem and module
immune cells56.
Dendritic cells (DC) play a key role in immune homeostasis in
the healthy intestine. DCs are key antigen presenting cells which
take up antigens (i.e. viral, cancer) and present small antigenic
peptides on their surface to prime T cells towards pro-
inflammatory (Th1) or anti-inflammatory (Th2) phenotypes. DC in
an immature state can lead to deletion of T cells or stimulation of
regulatory T cells57. The gut microbiota are able to drive DC to
prime these cells. In fact, L. reuteri and L. casei, stimulate IFN-
gamma production, and activate pro-inflammatory Th1 cells58.
Likewise, oral administration of B. infantis in mice stimulate DCs
which suppress Th2-biased responses59 and stimulate Th1 pro-
inflammatory responses which is required for virus elimination.
Monocytes are present in the peripheral blood which are
amongst the first cells to be in contact with bacteria and viruses.
They differentiate to tissue macrophages, where intestinal
microbiota or ingested probiotics interact with them to secrete
a number of cytokines. The pro-inflammatory cytokine, IL-12 is
secreted by macrophages which stimulate natural killer cells and
CD4+ Th1 cells to secrete IFN-gamma which are required for
elimination of viruses60. In addition, probiotics L. gasseri, L.
delbrueckii ssp. bulgaricus, B. bifidum, L. acidophilus strains induce
IFN-alpha production by monocytes60. The probiotic L. paracasei
DG increases TNF-alpha, IL-6, IL-8 of human monocyte cell line,
THP-161. Similarly, it was recently noted that S. thermophilus
induced TNF-alpha, IL-6, IL-8 profile which is required for anti-viral
effects62–64.
NK cells are important in the early immune response against
viral infections, in particular through clearance of virus-infected
cells. Lactobacillus probiotic strains are able to stimulate DCs to
secrete IL-12, which in turn activates NK cells to secrete IFN-
gamma, an essential cytokine for lung bacterial (S. aureus) and
viral elimination58,65.
Probiotics such as L. casei can also interact with Toll-like
receptors (TLR) on the epithelial cells, thereby, enhancing the
production of cytokines that play a major role in improving the
epithelial cells productivity and preventing their apoptosis which
enhances their survival and proliferation during restoration66,67.
Understanding the immune cell activation, cytokine profiles and
immune modulation is crucial providing a clear path for managing
viral infections.
PROBIOTICS AND RESPIRATORY TRACT INFECTIONS
Vaccines, antibiotics, and anti-viral medications have been
regularly used for the prevention and treatment of bacterial or
viral infectious diseases; however, the control of most infections
has not yet been fully achieved. Antimicrobial resistance is
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progressively emerging among many pathogenic bacteria, viruses,
parasites, and fungi21,68. Antibiotics are not recommended for
treating viral infections because of their inactivity against viruses
and disruption of the normal human microbiota. Therefore, other
approaches have been developed for the treatment and preven-
tion of bacterial or viral respiratory tract infections. These
modalities include bacteriophages, antimicrobial peptides, and
probiotics51. Probiotics exhibit potent antimicrobial activity
against several pathogens. In the past two decades, probiotics
have been proposed as antimicrobial agents against viruses
causing respiratory tract infections51. There are different possible
mechanisms of action supporting the activities of probiotics
against respiratory viruses; however, the most probable mechan-
isms are modulation of the innate immune system and enhance-
ment of acquired immune responses1. Based on previous studies
of different viral infections, it is evident that the prevention of
infectious diseases can be achieved by boosting and stimulating
human immune activity through the consumption of healthy,
balanced diets and the use of administrative supplements such as
vitamins, minerals, fiber, and probiotics51.
Several studies have shown that probiotics are useful for
preventing or treating respiratory tract infections caused by
viruses such as influenza and syncytial viruses through enhancing
the immunity of individuals via activating immunoglobulin A (IgA)
secretion and boosting the activity of Peyer’s plaques, neutrophils,
macrophages, natural killer cells, mesenteric lymph nodes, and
intraepithelial lymphocytes26,69. Oral probiotic strains have been
used to prevent or treat infections caused by influenza A,
influenza H1N1, and respiratory syncytial viruses by minimizing
the infectious symptoms, shortening the duration of infection,
reducing the virus levels in the lungs or nasal washings, producing
anti-viral components, promoting immune activity, and enhancing
health by reducing body weight loss during infection70–73.
Probiotic supplements containing L. paracasei, L. casei, and L.
fermentum significantly reduced the incidence of influenza-like
symptoms and upper respiratory infection in adults, who
commonly experience colds ≥4 times per year. Treated adults
exhibited significantly higher interferon (IFN)-γ levels in serum and
higher soluble IgA levels in the GI tract than untreated adults or
their own baseline results74.
In addition to oral probiotic administration, intranasal admin-
istration using nasal sprays and aerosolized formulations is
considered an effective and non-invasive approach for distributing
probiotics into cells in the lungs to modulate the microbiota and
treat or prevent several viral infections75–78. Several probiotics
species including B. breve, L. pentosus, L. casei, L. plantarum, L.
rhamnosus, L. delbrueckii ssp. bulgaricus, L. gasseri, L. reuteri, L.
lactis, and L. brevis have been intranasally or orally
administrated1,69.
Harata et al.79 found that the intranasal administration of L.
rhamnosus in mice infected with influenza H1N1 virus resulted in
significantly diminished symptoms and higher survival rates than
observed in control mice. They also reported that treated mice
exhibited higher cytotoxic activity in the lungs, elevated mRNA
expression of interleukin, tumor necrosis factor, and monocyte
chemotactic protein. Marchisio et al.80 noted that the intranasal
administration of S. salivarius effectively treated acute otitis media
in children aged 1–5 years. Nasal administration of different strains
of L. rhamnosus in mice conferred a protective effect against
influenza and respiratory syncytial virus infection81,82. Kawase
et al.83 reported that the oral administration of L. gasseri in mice
infected with the influenza H1N1 virus significantly ameliorated
clinical symptoms, reduced the viral load, and increased the mRNA
expression of interleukins and IFNs. Youn et al.84 found that
influenza virus-infected mice that were intranasally administered
Lactobacillus species had higher survival rates than untreated
mice.
PROBIOTICS, PREBIOTICS, AND COVID-19
The directly or indirectly positive impact of probiotics on the ACE
enzymes is well stated85. During food fermentation, probiotics
produce bioactive peptides with the capability to inhibit the ACE
enzymes by blocking the active sites86,87. Moreover, the debris of
the dead probiotic cells acted also as ACE inhibitors88. These
findings suggest that probiotics could be a potential blocker to
the ACE receptor that acts as a gateway for SARS-CoV-2 to attack
GI cells. The concept of using drugs to block the ACE receptors as
a treatment approach against COVID-19 was proposed by
Fernández-Fernández89, despite the otherwise opinion expressed
by Esler and Esler90. Imai et al.91 have stated a positive influence of
using an ACE blocker to reduce respiratory distress syndrome.
Prebiotics may also have an excellent potential effect against
COVID-19 by enhancing probiotics growth and survivability.
Furthermore, prebiotics could have a direct effect on GI symptoms
caused by COVID-19 via blocking the ACE enzymes. Yeh et al.92
systematically reviewed 12 studies that investigated the impact of
prebiotic and probiotic supplementation on influenza infection.
The authors concluded that the supplementation of probiotics
and prebiotics could improve hemagglutination inhibition anti-
body titers following the influenza vaccination.
SARS-CoV-2 is a newly emerging virus that currently lacks
curative treatments and vaccines. To date, no study has reported
the use of prebiotics and probiotics to treat or prevent COVID-19,
but the use of probiotics in the clinical treatment or prevention of
COVID-19 could be a suitable strategy. So far, several registered
trials that aim to investigate the efficiency of probiotics in treating
COVID-19 patients are ongoing93. Some patients with COVID-19
exhibited intestinal microbial dysbiosis characterized by low
numbers of different probiotic species such as Bifidobacterium
and Lactobacillus. This is could be an indicator of their weak
immunity, and therefore, it has been suggested that these
patients require nutritional support and prebiotic or probiotic
supplementation to re-normalize the intestinal flora balance and
decrease the risk of infection94. COVID-19 is a novel disease, and
humans have not acquired immunity against this disease.
Meanwhile, the dietary pattern of patients is an essential factor
for GI microbiota levels, diversity, structure, and function. There-
fore, balanced diets including probiotics-containing foods and
immunity-enhancing micronutrients such as polyphenols; vita-
mins A, C, and D; and minerals (mainly selenium and zinc) may
alleviate the risk of COVID-19 infection95. Food sources of
probiotics such as fermented products have a good potential to
prevent COVID-19. In previous research, the consumption of
fermented milk containing probiotic strains significantly reduced
the incidence of upper respiratory tract infections among healthy
infants, children, adults, and the elderly96–99.
Apparently, probiotic supplementation may be a suitable
strategy given prior reports of the potential application of
probiotics for preventing and treating several viral infections.
These observations support the administration of probiotics to
patients with COVID-19 despite the absence of solid evidence
supporting that these treatments can prevent or treat this
infectious disease. However, boosting the natural immunity of
the population using probiotics before, during, or after COVID-19
infection is rational.
Previous studies used large numbers of probiotic species and
strains, and their immunomodulatory effects were strain-
specific100. For example, Youn et al.84 reported that the protective
effects against influenza virus infection significantly varied among
Lactobacillus strains. Therefore, the effective strains of probiotics
should be selected on the basis of animal and human studies.
Concerning the required quantity of probiotics, they must be
consumed in sufficient quantities (>7 log CFU) to have protective
and curative effects against respiratory tract infections including
COVID-19. Microencapsulation should be used to protect
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probiotics against harsh conditions to permit their accumulation
at attachment sites in the intestine at sufficient levels. Other
factors associated with the beneficial effects of probiotics in
preventing or treating diseases such as COVID-19 including the
time of administration in the context of disease, the probiotics
dose, treatment duration, and the health and microbiota status of
the host. Clinical trials considering these factors should be
launched in the near future.
It has been demonstrated that the numbers and biodiversity of
GI microbes usually decreases with age and antibiotics therapy.
This dysbiosis has been remarkably linked to several infectious,
metabolic, or inflammatory diseases and conditions such as
malnutrition, colon cancer, obesity, diabetes, and atherosclero-
sis101. Patients with disordered microbiota and the elderly are the
most susceptible to COVID-19. Therefore, probiotics supplementa-
tion in those groups could likely improve the ability of the GI
microbiota to modulate immune activity and thus prevent viral
infections including COVID-19.
In a meta-analysis of 52 published studies that investigated the
ability of probiotics to prevent or treat several disorder conditions,
the strongest evidence concerning the efficiency of probiotics was
observed for five diseases including acute respiratory tract
infections102. In another meta-analysis, King et al.103 evaluated
17 randomized controlled trials that assessed the preventive
effects of probiotics against acute lower digestive tract infections,
acute respiratory tract infections, or acute otitis media in infants
and/or children. Probiotics comprising single or combinations of
Lactobacillus and Bifidobacterium strains were delivered to the
target sample via food or supplements for 4 days to 9 months.
Children who were treated with probiotics had a lower risk of
requiring antibiotic prescriptions than untreated children. There-
fore, probiotics may reduce the risk of common acute infections
and thus reduce antibiotic use in infants and children. Further, the
effects of probiotics on respiratory tract infections were investi-
gated in a meta-analysis of 23 randomized controlled trials
involving 6269 children. The results illustrated that probiotic
consumption significantly reduced the severity of symptoms of
infected children and the duration of infection104.
Research is needed to determine the accurate mechanisms of
action of probiotics against coronaviruses including SARS-CoV-2 in
healthy or infected animal models. These studies may lead to a
better understanding of the bacterial dynamics in the GI tract.
Animal or human studies could be used to assess the direct
effects of intranasal probiotics through targeting pathogens in the
lungs and indirect effect occurring through the modulation of
immune activity. These studies may be helpful for treating viral
infections such as COVID-19.
To date, the health effects of probiotics have been attributed to
various activities including their ability to support intestinal
integrity and maintain intestinal permeability, competition with
pathogens for nutrients and attachment sites, the regulation of
immune cell activity against invading pathogens, and the
prevention of excessive immune responses and inflammation100.
Further studies are needed to examine the activity of probiotics
against different coronaviruses such SARS-CoV-1, SARS-CoV-2, and
MERS-CoV to fully understand their underlying mechanisms
against viruses. Studies are also required to determine any
adverse effects of probiotic supplementation.
CONCLUSIONS
Probiotics are live microorganisms that confer health benefits
when consumed in adequate amounts, including enhanced
immune activity and the clearance of respiratory tract infections.
It is evident that probiotics can reduce the incidence and severity
of diseases, suggesting their promise for treating or preventing
COVID-19. Probiotics could help prevent COVID-19 by maintaining
the human GI or lung microbiota because dysbiosis plays a major
role in the susceptibility of people to infectious diseases. In vitro
and clinical studies are required to examine the potential
preventive and curative effects of probiotics against SARS-CoV-2
infection.
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